Orantinib

Orantinib, also known as TSU-68;SU6668, is an orally bioavailable receptor tyrosine kinase inhibitor. Orantinib binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation.
Supplier Alfa Cytology
Product # BC0459
Pricing 10.0 mg, inquire
Feedback